Structure Therapeutics Inc (GPCR)
33.41
+3.31
(+11.00%)
USD |
NASDAQ |
Nov 22, 16:00
33.44
+0.03
(+0.09%)
After-Hours: 20:00
Structure Therapeutics Cash from Operations (Quarterly): -19.70M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -19.70M |
| June 30, 2024 | -26.39M |
| March 31, 2024 | -34.08M |
| December 31, 2023 | -21.73M |
| September 30, 2023 | -20.56M |
| June 30, 2023 | -16.89M |
| Date | Value |
|---|---|
| March 31, 2023 | -20.31M |
| December 31, 2022 | -12.03M |
| September 30, 2022 | -10.48M |
| June 30, 2022 | -10.10M |
| March 31, 2022 | -13.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-34.08M
Minimum
Mar 2024
-10.10M
Maximum
Jun 2022
-18.71M
Average
-19.70M
Median
Sep 2024
Cash from Operations (Quarterly) Benchmarks
| Viking Therapeutics Inc | -21.96M |
| Eli Lilly and Co | 3.712B |
| Novo Nordisk AS | 6.658B |
| Pfizer Inc | 6.714B |
| Amgen Inc | 3.571B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -189.04M |
| Cash from Financing (Quarterly) | -0.757M |
| Free Cash Flow | -104.33M |
| Free Cash Flow Per Share (Quarterly) | -0.3562 |
| Free Cash Flow Yield | -6.26% |